Skip to content
Try Mental Wellness – Lifestyle
Author:
DECHRA PHARMACEUTICALS LIMITED
Dechra Announces FDA Approval of CosACTHen® (cosyntropin injection), the First and Only Cosyntropin Approved Specifically for Canine Patients
May 19, 2026
Dechra to Establish Global Headquarters in Boston, Strengthening U.S. Leadership and Innovation Presence
March 11, 2026